Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12...345678910111213...3637»
  • ||||||||||  MatchR a preclinical platform of models resistant to innovative therapies (Section 6; Poster Board #2) -  Mar 14, 2023 - Abstract #AACR2023AACR_7723;    
    P=N/A
    Our focus is the development of models from different cohorts: Androgen receptor inhibitors in castration-resistant prostate cancer, (18 PDX), ALK inhibitors in lung cancers (16 PDX including 3 post brigatinib, 7 post Lorlatinib and 6 Alectinib), EGFR inhibitors in lung cancers (33 PDX includind 24 post osimertinib), FGFR inhibitors in urothelial carcinoma and cholangiocarcinoma (29 PDX including 14 post erdafitinib, 4 post pemigatinib, 4 post futibatinib) and KRAS inhibitors in lung cancer and pancreatic cancers (20 PDX). Overall, the MATCH-R study provides a unique preclinical platform to identify resistance mechanisms to innovative therapies and to develop next generation therapeutic strategies.
  • ||||||||||  NVL-655 / Nuvalent, Alecensa (alectinib) / Roche
    Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation (Section 20; Poster Board #19) -  Mar 14, 2023 - Abstract #AACR2023AACR_6212;    
    P1/2
    Using a xenograft model derived from an alectinib-relapsed patient, we showed that NVL-655 had high intracranial activity against brain tumors bearing the ALK G1202R mutation that confers resistance to multiple ALK TKIs. NVL-655 is being evaluated in a Phase 1/2 clinical trial for patients with advanced NSCLC and other solid tumors harboring ALK rearrangement or activating ALK mutation (ALKOVE-1): NCT05384626.
  • ||||||||||  Clinical use of next-generation sequencing panel in pediatric oncology patients (Section 44; Poster Board #8) -  Mar 14, 2023 - Abstract #AACR2023AACR_4723;    
    Application of NGS panel in pediatric cancer aid in diagnosis, treatment decision, clinical trial enrollment and germline risk determination. Although there are not many cases linked with molecular target-based therapy, it is leading to clinical benefits in pediatric patients and more understanding genomic profiling of pediatric cancer.
  • ||||||||||  Alecensa (alectinib) / Roche
    Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC (Section 19; Poster Board #19) -  Mar 14, 2023 - Abstract #AACR2023AACR_2409;    
    To test the relevance of these findings in vivo, we took advantage of the inability of murine HGF to activate human cMET by comparing the response of ALK+ xenograft tumors to front-line ALKi alectinib between NSG mice and NSG-derivative strain with humanized HGF...Our findings indicate that focusing on a single resistance mechanism at a time is unlikely to induce strong, durable responses. Instead, tackling the issue of therapy resistance necessitates the consideration of multiple resistance mechanisms as well as the moving target nature of tumors under therapy.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. (Pubmed Central) -  Mar 14, 2023   
    Instead, tackling the issue of therapy resistance necessitates the consideration of multiple resistance mechanisms as well as the moving target nature of tumors under therapy. The tumor nadir volume in patients with ALK-rearranged advanced NSCLC treated with alectinib can be predicted by the liner regression model and consists of approximately 30% of the baseline volume minus 5 cm, providing additional insights into precision therapy monitoring and potential guides for local ablative therapy to prolong disease control.
  • ||||||||||  Review, Journal, Metastases:  Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review. (Pubmed Central) -  Mar 10, 2023   
    This review serves as a resource summarizing data from key clinical trials with ALK inhibitors to aid in decision making when tailoring treatment for patients. Future research in the field includes real world analysis of efficacy and toxicity of next-generation ALK-inhibitors, identification of mechanisms of tumor persistence and acquired resistance, development of novel ALK inhibitors, and use of ALK-TKIs in earlier stage disease.
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
    Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_974;    
    As only direct comparison trials with crizotinib were found, a systematic review with network meta-analysis (NMA) was developed to compare the efficacy (PFS and OS) and safety of lorlatinib with alectinib, with crizotinib as the common comparator. Considering the NMA and the lower cost of treatment compared to alectinib, lorlatinib was incorporated into the Brazilian private healthcare system in May 2022, becoming another treatment option for patients with ALK+ NSCLC.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Synthesis and Anti-Angiogenic Activity of Novel c(RGDyK) Peptide-Based JH-VII-139-1 Conjugates. (Pubmed Central) -  Feb 25, 2023   
    targeting oligopeptide c(RGDyK) through amide, carbamate and urea linkers...In conclusion, most conjugates retained the inhibitory potency against SRPK1 as JH-VII-139-1 and demonstrated antiproliferative and antiangiogenic activities. Further animal model experiments are needed to uncover the full potential of such peptide conjugates in cancer therapy and angiogenesis-related diseases.
  • ||||||||||  Drug treatment management of advanced ALK-positive non-small cell lung cancer in Spain. A real-world cross-sectional analysis (Exhibition and Poster area) -  Feb 14, 2023 - Abstract #ELCC2023ELCC_341;    
    In 2L, alectinib (29/32%), lorlatinib (27/30%), and brigatinib (9/10%) were the most prescribed treatments; and in 3L+, immunotherapy (IO) (27/31%), lorlatinib (18/21%), and platinum-based regimens (18/21%)...Conclusions New drugs marketed in Spain for mNSCLC ALK+ patients seem to have gained importance in 2L and 3L. Additional approvals are expected so clinical practice could continue evolving.
  • ||||||||||  Retrospective data, Review, Journal, Metastases:  Comparative Efficacy of ALK Inhibitors for Treatment-Na (Pubmed Central) -  Feb 12, 2023   
    While lorlatinib was superior to brigatinib for PFS in the overall patient population, no significant difference between the two was found in the subgroup of patients with CNS metastases. These results can serve as a foundation for basic, clinical, and translational research and guide clinical oncologists in developing individualized treatment strategies for patients with ALK-p, ALK inhibitor-naive advanced NSCLC.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules. (Pubmed Central) -  Feb 7, 2023   
    In this article, we use a statistical approach to compare the efficacy and safety of targeted drugs that have been used in the first-line treatment of anaplastic lymphoma kinase mutations to improve the reference for clinicians to make treatment decisions in the real world. There are no current guidelines for oral targeted therapy in patients with swallowing disturbance, but alectinib administered orally by opening the capsules and suspending the contents in water can be a treatment option in patients with ALK-positive NSCLC and swallowing difficulty.
  • ||||||||||  Alecensa (alectinib) / Roche
    Preclinical, Journal, IO biomarker:  Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. (Pubmed Central) -  Feb 6, 2023   
    Analysis of pre-treatment patient biopsies from ALK+ tumors revealed an association of neutrophil content with shorter time to progression. Combined, these data support a role for adaptive immunity in durability of TKI responses and demonstrate that the immune cell composition of the tumor microenvironment is predictive of response to alectinib therapy.
  • ||||||||||  Alecensa (alectinib) / Roche
    New P1/2 trial, Metastases:  Alectinib Pharmacokinetic in Patients With NSCLC (clinicaltrials.gov) -  Feb 6, 2023   
    P1/2,  N=45, Recruiting, 
  • ||||||||||  Alecensa (alectinib) / Roche
    New trial:  The Food-effect on Alectinib Pharmacokinetics (clinicaltrials.gov) -  Feb 2, 2023   
    P=N/A,  N=10, Not yet recruiting,